New Dual-Action eye drug shows promise in early trial for Diabetes-Related vision loss

NCT ID NCT05940428

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a new eye injection called ASKG712 in 10 people with diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The drug targets two proteins that cause leakage and abnormal blood vessel growth. The main goal was to check safety and how the body processes the drug, not yet to prove it works. Results will guide future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ASKG712 (a protein injection that blocks two factors involved in abnormal blood vessel growth and leakage)
What this could lead to
If successful, this could lead to a new treatment option for diabetic macular edema that targets two pathways at once, potentially offering better or longer-lasting vision improvement.
What could go wrong
This is a very early (Phase 1) study with only 10 participants, so safety and dosing are the main focus—not yet proof of effectiveness. The treatment is injected directly into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.